Table 2: Changes in ACT, UCT, FEV1, FeNO, and blood eosinophils before and after biologic treatment.

Biologic Disease Parameter   Mean Median Std Dev p-value
Omalizumab   ACT Before 16.6 16 4.34 <0.001
  After 21 21 3.2
Asthma FEV1 Before 2.4 2.47 0.94 0.254
  After 2.73 2.76  0.88
  FeNO ‡ Before 43.9  40 29.1 0.022
  (ppb) After 15.8 16 5.68
Chronic UCT § Before 6.7 6.5  4.47 <0.001
Urticaria After 12.02 13  4.17
Dupilumab Asthma ACT Before 15  15 5.92 <0.001
After 19.8  21 4.64
FEV1 Before 2.56 2.66  0.13 0.33
After 2.76 2.75  0.15
FeNO ‡ Before 55.9 41 34.37 0.003
(ppb) After 31.4  27 22.02
Benralizumab Asthma ACT Before 14.1 14  5.15 0.004
After 19.3  21 5.81
FEV1 Before 2.2 1.94  0.42 0.602
After 2.4 2.45  0.68
FeNO ‡ Before 94.6 78 76.42 0.309
(ppb) After 59.7 58 48.34
BEC Before 0.77 0.53  0.84 <0.001
(109/L) After 0.03  0.01 0.05
Mepolizumab Asthma +EGPA ACT Before 18.7 20 15-21 NA
After 21.7 20.5 20-24
BEC Before 0.88 0.56 0.29 NA
(x109/L) After 0.09 0.06 0.08

† ACT >19, well-controlled asthma
‡ <26ppb indicates lack of eosinophilic inflammation
§ ≥12: well controlled urticaria
Abbreviations: ACT, Asthma Control Test; FEV1, Forced Expiratory Volume in 1 second; FeNO, Fractional exhaled Nitric Oxide; UCT, Urticaria
Control Test; BEC, Blood Eosinophil Count.